CN107648311A - With antiviral and composition and medicine of antiinflammatory action - Google Patents
With antiviral and composition and medicine of antiinflammatory action Download PDFInfo
- Publication number
- CN107648311A CN107648311A CN201710759720.XA CN201710759720A CN107648311A CN 107648311 A CN107648311 A CN 107648311A CN 201710759720 A CN201710759720 A CN 201710759720A CN 107648311 A CN107648311 A CN 107648311A
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- andrographolide
- medicine
- scutellaria root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 17
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 72
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims abstract description 52
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims abstract description 52
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 31
- 229930003944 flavone Natural products 0.000 claims abstract description 31
- 235000011949 flavones Nutrition 0.000 claims abstract description 31
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000207929 Scutellaria Species 0.000 claims abstract description 30
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940015301 baicalein Drugs 0.000 claims abstract description 30
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 30
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims abstract description 29
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000002596 lactones Chemical class 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 claims description 7
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 claims description 7
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 claims description 7
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 claims description 7
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 238000002386 leaching Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- GVRNTWSGBWPJGS-YSDSKTICSA-N 4-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)CC1=CCOC1=O GVRNTWSGBWPJGS-YSDSKTICSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- GVRNTWSGBWPJGS-UHFFFAOYSA-N deoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CCC1=CCOC1=O GVRNTWSGBWPJGS-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 231100000028 nontoxic concentration Toxicity 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229940100050 virazole Drugs 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108700002722 mouse granuloma Proteins 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
With antiviral and composition and medicine of antiinflammatory action.Described composition is made up of scutellaria root flavone general aglycone extract and total andrographolide extract, wherein the weight ratio of the scutellaria root flavone general aglycone extract counted using baicalein and the total andrographolide extract counted using andrographolide is 1:(0.05‑0.5).Using said composition as active ingredient, can be collectively constituted to acceptable auxiliary and/or adding ingredient in medicine corresponding has antiviral and antiinflammatory action medicine, preferably oral type pharmaceutical preparation.Said composition and corresponding medicine can have more superior effect and application value compared to the similar drugs of existing report in terms of pharmacoeconomics and drug action.
Description
Technical field
The present invention relates to a kind of improved with antiviral and the composition of antiinflammatory action and corresponding medicine.
Background technology
Radix scutellariae and Herba Andrographitis are clearing heat and detoxicating conventional Chinese medicine, and radix scutellariae principle active component is scutelloside, wogonoside, Huang
A kind of reed mentioned in ancient books element（That is baicalein）, the flavone compound such as wogonin, it is considered that the effect of wherein baicalein is better than radix scutellariae
Glycosides.The principle active component of Herba Andrographitis is the lactone chemical combination such as andrographolide, neoandrographolide, deoxyandrographolide
Thing.One kind is disclosed in CN1234355B Chinese patent to be made up of than 10/2 ~ 10/20 with weight baicalein/andrographolide
There is the anti-infective and pharmaceutical composition of antiinflammatory action.In-depth study finds that the pharmaceutical composition also has can be further
Optimization, the improvements for improving and improving.
The content of the invention
On the basis of above-mentioned literature content, invention further provides a kind of more optimization with improved with disease-resistant
The composition of poison and antiinflammatory action, and there is the antiviral and corresponding medicine of antiinflammatory action using said composition as active ingredient
Thing.
The present invention has the antiviral and composition of antiinflammatory action, is total by scutellaria root flavone general aglycone extract and Herba Andrographitis
Lactone extract forms, wherein, the scutellaria root flavone general aglycone extract in terms of baicalein and the Herba Andrographitis in terms of andrographolide
The weight ratio of total lactone extract is 1:(0.05-0.5).On this basis, the scutellaria root flavone general glycosides in terms of baicalein
First extract is with the further preferred weight ratio of the total andrographolide extract counted using andrographolide as >=1:0.1 and ＜
1:0.2。
To reduce and avoiding to deposit in the scutellaria root flavone general aglycone extract and/or total andrographolide extract as far as possible
Multiple types and/or other compositions of proportional quantities there may be or the adverse effect brought, the more preferable mode of above-mentioned composition be,
Gross weight >=60% of baicalein and wogonin in described scutellaria root flavone general aglycone extract, and/or described Herba Andrographitis
Gross weight >=20% of andrographolide and neoandrographolide in total lactone extract so that the quality of above-mentioned composition and
Its effect can have more reliable guarantee and raising.
In the composition of above-mentioned form, described scutellaria root flavone general aglycone extract is currently reported except that can use
And/or the various methods used are obtained outside, it is preferred to employ the applicant is reported in Chinese patent CN104606288A
The scutellaria root flavone general aglycone extract that is prepared of method.That is, under conditions of 0 ~ 30 DEG C and pH values 2 ~ 7, to radix scutellariae medicinal materials
Starting material with water extracts, and collects the remaining dregs of a decoction after leaching liquor and is put under conditions of pH values 5 ~ 7 in boiling water and continues to decoct extraction,
Collect after decocting extract solution, leaching liquor is merged with decocting extract solution, maintained 3 ~ 20 hours under the conditions of room temperature to 70 DEG C of ＜, receipts
After collecting sediment or being further dried, described scutellaria root flavone general aglycone extract is produced.This method not only it is easy to operate and
Cost is low, and extract obtained high income.
Total andrographolide extract described in composition for above-mentioned form, second is soluble in due to being insoluble in water
Alcohol, therefore except various methods that are currently reported and/or using can be used, such as macroreticular resin chromatography, solvent extraction
Or the mode such as column chromatography for separation method obtains outer, preferable reference tinkling of pieces of jade etc. " Study on extraction of Herba Andrographitis "（Shi Zhen traditional Chinese medical science state
Medicine, 2003,14 (8):458）, and/or Li Zhi enjoys etc. " progress of total andrographolide "（When treasure's traditional Chinese medical science traditional Chinese medicines, 2012,23
(11):2854）Etc. the method for document report, i.e. following manner alcohol extracting-water precipitating method：
Method 1, after Herba Andrographitis is crushed, extracted with the ethanol-water solution that volume content is 40 ~ 90%, after extract solution removes ethanol
Carry out separation of solid and liquid is diluted with water, obtains the total andrographolide extract of precipitated form；Or
Method 2, after Herba Andrographitis is crushed, extracted with the ethanol-water solution that volume content is 40 ~ 90%, extract solution is through activated carbon
And/or UF membrane decolourizes after cleaning, and removes ethanol, carry out separation of solid and liquid is diluted with water, the Herba Andrographitis for obtaining precipitated form is total
Lactone extract；
The extraction with the ethanol-water solution that volume content is 40 ~ 90%, including with the diacolation of the solution, backflow, ultrasound
Mode is extracted.
The preparation method of above-mentioned total andrographolide extract is simple and feasible, low production cost.
On the basis of above-mentioned composition, using the composition as active ingredient, with medicine in acceptable auxiliary and/
Or adding ingredient, according to current conventional technique and method, can be prepared into the corresponding antiviral and medicine of antiinflammatory action.
For example, as a kind of preferable form, be can with can be with received disintegrant, excipient, lubricant, viscous in oral formulations
After the conventional auxiliary such as mixture, filler/addition composition mixing, handled by corresponding existing common process and method, you can system
As the medicine of the oral type preparation such as the sustained release agent of corresponding tablet, pill, capsule, or appropriate format, controlled release agent.
It is known in the art that the performance of herbal medicine efficacy effect, has the synergism action effect of multicomponent, Mutiple Targets, multipath.
Now there are some researches show in scutellaria root flavone general aglycone extract in addition to baicalein, also containing aglycons such as wogonin, qroxylin As
Constituents, though also can have baicalein it is similar the effect of, yet have its each the characteristics of；In total andrographolide extract
In addition to andrographolide, also containing neoandrographolide, deoxyandrographolide, Dehydro and drographolide etc., except with wearing
Outside the similar effect of heart lotus lactone, yet have its each the characteristics of.Further investigation shows, the combination of these compositions, except can divide
Outside the other effect to baicalein and andrographolide has been strengthened, not only in its respective antiviral and comprehensive function of anti-inflammatory
On, and in terms of the antiviral and anti-inflammatory comprehensive function after described two extract combinations, significant collaboration can also be played
Synergistic effect and complementation, drug action can be substantially better than corresponding proportion amount and be made up of baicalein/andrographolide merely
Pharmaceutical composition.Simultaneously, moreover it is possible to avoid obtaining baicalein and andrographolide composition to be simple, and make to include wogonin, thousand
The loss and wave of effective ingredient in other more beneficiating ingredients such as layer paper factor A, neoandrographolide, deoxyandrographolide
Take, make Chinese material medicine resource obtain more fully and preferably utilizing, be significantly reduced cost and price, benefit the people's livelihood.Therefore in medicine
Significant superiority is all had more in terms of thing economics and drug action.
Embodiment by the following examples is described in further detail to the above of the present invention again.But
The scope that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to following example.The above-mentioned technological thought of the present invention is not being departed from
In the case of, the various replacements or change made according to ordinary skill knowledge and customary means, the present invention all should be included in
In the range of.
Embodiment
Embodiment 1
Take 20 kilograms of radix scutellariae medicinal materials to crushed 10 mesh sieves, add 250 liters of water, leaching is stirred under conditions of about 15-25 DEG C and pH value ~ 3
0.5-1 hours are carried, are filtered, filtrate high speed centrifugation collects leaching liquor to clarifying, standby.The dregs of a decoction are added in the 8-10 times of boiling water measured
PH value ~ 6 are adjusted, are decocted 0.5 hour, are filtered, filtrate is standby；The dregs of a decoction add 8-10 times to measure decocting to boil 1-2 times again, 0.5 hour every time, filter
Cross, merging filtrate, high speed centrifugation is collected extract solution, merged with above-mentioned leaching liquor to clarifying, and adjusts pH value ~ 5, is heated to 50 DEG C of left sides
The right side is simultaneously incubated 8-10 hours, separates out precipitation；Filtering, wash, dry, produce scutellaria root flavone general aglycone extract, yield is
10.2%, baicalein and wogonin content are 67.2%, wherein, radix scutellariae cellulose content is 55.3%.
Herba Andrographitis crushes, and by percolation routine operation, is first infiltrated with appropriate 50% ethanol, closed placement 3-6 h, makes medicinal powder
Uniform wet and expansion, load percolator, after adding 50% alcohol dipping 3-5 h, with 2-4 mL/min × kg speed diacolation, receive
Collect the 6-8 times of percolate measured, be recovered under reduced pressure and eliminate ethanol, be diluted with water to about 1 g/mL（In terms of crude drug）, centrifugation, solid-liquid point
From, drying is precipitated, produces total andrographolide extract, yield 4.0%, the weight of andrographolide and neoandrographolide
Content is 23.4%, wherein, Determination of Andrographolide 18.5%.
Above-mentioned scutellaria root flavone general aglycone extract 1000g is taken respectively（In terms of baicalein）, total andrographolide extract
100g（In terms of andrographolide）, add supplementary product starch 1000g, be well mixed, granulation, suppress 10000, produce of the present invention
Tablet.
Embodiment 2
Take 20 kilograms of radix scutellariae medicinal materials to crushed 20 mesh sieves, add 200 liters of water, leaching is stirred under conditions of about 0-10 DEG C and pH value 5 ~ 6
0.5-1 hours are carried, are filtered, filtrate high speed centrifugation collects leaching liquor to clarifying, standby.The dregs of a decoction are added in the 10-12 times of boiling water measured
PH value ~ 6 are adjusted, are decocted 0.5 hour, are filtered, filtrate is standby；The dregs of a decoction add 6-10 times to measure decocting to boil 1-2 times again, 0.5 hour every time, filter
Cross, merging filtrate, high speed centrifugation is collected extract solution, merged with above-mentioned leaching liquor to clarifying, and adjusts pH value ~ 6, is heated to 40 DEG C of left sides
The right side is simultaneously incubated 10-15 hours, separates out precipitation；Filtering, wash, dry, produce scutellaria root flavone general aglycone extract, yield is
9.5%, baicalein and wogonin content are 75.3%, wherein, radix scutellariae cellulose content is 61.6%.
Herba Andrographitis crushes, and by circumfluence method routine operation, is extracted 2-3 times with 6-10 times of 70% alcohol reflux measured, each 1-2
Hour, filtration, filtrate is decolourized through activated carbon decolorizing and/or UF membrane after removal of impurities, eliminates ethanol, is diluted with water to about 2 g/mL
（In terms of crude drug）, centrifugation, separation of solid and liquid, drying is precipitated, produces total andrographolide extract, yield 2.9%, in Herba Andrographitis
The weight content of ester and neoandrographolide is 31.8%, wherein, Determination of Andrographolide 25.1%.
Above-mentioned scutellaria root flavone general aglycone extract 1000g is taken respectively（In terms of baicalein）, total andrographolide extract
200g（In terms of andrographolide）, it is added in PEG-6000 fused solutions, stirs, 10000 is made in pill dripping machine
Grain ball, produce pill-type medicine of the present invention.
Embodiment 3
The scutellaria root flavone general aglycone extract 1000g of Example 1 respectively（In terms of baicalein）, total andrographolide extract
500g（In terms of andrographolide）, dry-pressing granulation, 10000, dress glue capsule, produce capsule of the present invention.
Embodiment 4
The scutellaria root flavone general aglycone extract 1000g of Example 2 respectively（In terms of baicalein）, total andrographolide extract
50g（In terms of andrographolide）, add supplementary product starch appropriate, be well mixed, granulation, suppress 10000, produce of the present invention
Tablet.
With the scutellaria root flavone general aglycone extract described in the embodiment of the present invention 1, total andrographolide extract by not year-on-year
The composition of example composition has carried out antiviral, antiinflammatory action pharmacodynamics test as trial drug.Meanwhile according to a conventional method
Using column chromatography for separation, the isolated baicalein single component from scutellaria root flavone general aglycone extract（Content >=98.0%）, from
Isolated andrographolide single component in total andrographolide extract（Content >=98.0%）, as active ingredient, with
The foregoing CN1234355B composition in the form of single baicalein/andrographolide carries out contrast test.
First, antivirus action
Using histocyte median infective dose（TCID50）Method, the inhibition according to medicine to cytopathy, with determine
Antiviral effect of the trial drug to Adv3 and RSV.
1. drug solution preparing：Two-fold dilution is carried out to above-mentioned each trial drug with RPMI-1640, its liquor strength is respectively
1.0mg/ml, 0.5mg/ml, 0.25mg/ml, 0.125mg/ml（In terms of baicalein and andrographolide）.The concentration of virazole
Respectively 0.062,0.031,0.015 and 0.008 mg/ml.
2. the maximal non-toxic concentration mensuration of pair Vero cells and Hep-2 cells：In the Vero individual layers of 96 porocyte culture plates
The trial drug of various concentrations is separately added into cell and Hep-2 cell monolayers, puts 37 DEG C and 5% CO296 hours in incubator,
Cytopathy is observed, determines its maximal non-toxic concentration to Vero cells and Hep-2 cell monolayers.
3. pair Adv3 viruses cause the suppression experiment of Vero cytopathies：In the Vero cell monolayers of 96 porocyte culture plates
It is interior, the infection Adv3 10TCID per hole50(7LgTCID50) virus liquid, hypsokinesis in 2 hours prevents or cure a disease venom, per hole in add it is different dense
The trial drug or virazole of degree, culture observe cytopathy after 96 hours.
4. pair RSV viruses cause the suppression experiment of Hep-2 cytopathies：In the Hep-2 cell monolayers of 96 porocyte culture plates
It is interior, the infection RSV 10TCID per hole50(6LgTCID50) virus liquid, hypsokinesis in 2 hours prevents or cure a disease venom, per hole in add it is different dense
The trial drug or virazole of degree, culture observe cytopathy after 96 hours.
5. experimental result
（1）Each trial drug is respectively less than 2.0mg/ml to the maximal non-toxic concentration of Vero cells through CPE methods measure.Formal medicine
In vitro antibacterial test is then carried out using the medicine less than 2.0mg/ml in experiment.
（2）Each trial drug causes the inhibitory action of Vero cytopathies to Adv3 viruses, and Hep-2 cells are caused to RSV viruses
The inhibitory action of lesion.Result of the test is as shown in table 1.Wherein, I~IV group of trial drug is the medicine group of the present invention of different proportion
Compound（10:0.5,10:1,10:2,10:5）, V and VI two groups be respectively CN1234355B pharmaceutical composition（10:1 and 10:2）.
The result of table 1 shows that scutellaria root flavone general aglycone extract/Herba Andrographitis of the various proportion of composing of the present composition is total
Lactone extract composition（I~IV）Significant inhibitory action is respectively provided with to Adv3 and RSV, and is better than corresponding proportion amount
CN1234355B pharmaceutical compositions（V and VI）, wherein it is preferably in a proportion of 10 in the present composition:1（Ⅱ）With 10:2
（Ⅲ）.
2nd, antiinflammatory action
On the basis of above-mentioned result of the test, with scutellaria root flavone general aglycone extract/total andrographolide extract (with baicalein
With andrographolide meter, 10:1（Ⅰ）、10:2（Ⅱ）) pharmaceutical composition of the present invention, and baicalein/Chuan heart lotus Nei Zhi ﹝ 10:1
（Ⅲ）、10:2（Ⅳ）﹞ drugs compareds composition is the experimental study that trial drug has further carried out following antiinflammatory actions.
1. the influence male mice 60 of pair mouse granuloma induced by implantation of cotton pellets is only randomly divided into 6 groups, in yellow Jackets（40mg/
kg）Under anesthesia, sterilized under armpit on the right side of each mouse, otch 0.3cm, be subcutaneously implanted 10mg sterilizing cotton balls, suture sterilization.Hereafter it is every
The administration of day each group ig, once a day, continuous 14d.24h wins the cotton balls with granulation tissue and dried in 60 DEG C of 18h after not secondary administration
After weigh, subtract cotton balls weight with the cotton balls weight with granulation（10mg）, as granulation tissue weight, as a result as shown in table 2.By
The visible drug test sample scutellaria root flavone general aglycone extract/total andrographolide extractive composition of the present invention of table 2 (（10:1、
10:2,0.4g/kg（In terms of baicalein and andrographolide））, there is obvious inhibitory action to cotton balls granulation tissue weight, and
It is better than baicalein/andrographolide composition（10:1、10:2）Corresponding dosage group.
2. the influence mouse 60 of pair mouse peritoneal capillary permeability is only randomly divided into 10 groups, after 1h is administered in ig, tail
It is injected intravenously 1% Evans blue 0.1ml/ only, and 0.6% acetic acid 0.2ml/ is injected intraperitoneally simultaneously only, after 20min, draws cervical vertebra to put to death
Animal, abdominal cavity is cut off, with 5ml distilled water flushings abdominal cavity for several times, draw abdominal cavity eluate centrifugation 5min, 590nm measure absorption value
（OD）, as a result as shown in table 2.
The result of table 2 shows, drug test sample scutellaria root flavone general aglycone extract/total andrographolide extract of the present invention
Composition（10:1、10:2）, can substantially suppress mouse peritoneal capillary permeability, and be better than baicalein/andrographolide
Composition（10:1、10:2）Corresponding dosage group.
Above-mentioned result of the test is clearly shown, total using scutellaria root flavone general aglycone extract proposed by the present invention and Herba Andrographitis
The composition of lactone extract composition form, and the medicine using said composition as effective medicinal ingredient, its is antiviral and anti-
What the positive effect of inflammation effect was better than including CN1234355B single uses by baicalein and andrographolide as effective medicine
With the pharmaceutical composition of composition, be a kind of further optimization with more notable superiority on its basis composition and
Medicine, there is gratifying DEVELOPMENT PROSPECT and value.
Claims (7)
1. with the antiviral and composition of antiinflammatory action, it is characterized in that always interior by scutellaria root flavone general aglycone extract and Herba Andrographitis
Ester extract forms, wherein the scutellaria root flavone general aglycone extract in terms of baicalein and the Herba Andrographitis in terms of andrographolide are always interior
The weight ratio of ester extract is 1:(0.05-0.5).
2. composition as claimed in claim 1, it is characterized in that the scutellaria root flavone general aglycone extract in terms of baicalein
With the weight ratio of total andrographolide extract counted using andrographolide as >=1:0.1 and ＜ 1:0.2.
3. composition as claimed in claim 1 or 2, it is characterized in that the baicalein in described scutellaria root flavone general aglycone extract
With gross weight >=60% of wogonin, andrographolide and neoandrographolide in described total andrographolide extract
Gross weight >=20%.
4. composition as claimed in claim 1 or 2, it is characterized in that described scutellaria root flavone general aglycone extract is using China
The scutellaria root flavone general aglycone extract that patent CN104606288A method is prepared.
5. composition as claimed in claim 1 or 2, it is characterized in that described total andrographolide extract is to use following sides
The product that method is prepared：
Method 1, after Herba Andrographitis is crushed, extracted with the ethanol-water solution that volume content is 40 ~ 90%, after extract solution removes ethanol
Carry out separation of solid and liquid is diluted with water, obtains the total andrographolide extract of precipitated form；Or
Method 2, after Herba Andrographitis is crushed, extracted with the ethanol-water solution that volume content is 40 ~ 90%, extract solution is through activated carbon
And/or UF membrane decolourizes after cleaning, and removes ethanol, carry out separation of solid and liquid is diluted with water, the Herba Andrographitis for obtaining precipitated form is total
Lactone extract；
The extraction with the ethanol-water solution that volume content is 40 ~ 90%, including with the diacolation of the solution, backflow, ultrasound
Mode is extracted.
6. with the antiviral and medicine of antiinflammatory action, it is characterized in that using the composition of one of claim 1 to 5 as effectively into
Point, collectively constituted with acceptable auxiliary and/or adding ingredient in medicine.
7. medicine as claimed in claim 6, it is characterized in that described medicine is oral type preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710759720.XA CN107648311B (en) | 2017-08-30 | 2017-08-30 | Composition and medicine with antiviral and antiinflammatory effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710759720.XA CN107648311B (en) | 2017-08-30 | 2017-08-30 | Composition and medicine with antiviral and antiinflammatory effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107648311A true CN107648311A (en) | 2018-02-02 |
| CN107648311B CN107648311B (en) | 2020-07-10 |
Family
ID=61128004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710759720.XA Active CN107648311B (en) | 2017-08-30 | 2017-08-30 | Composition and medicine with antiviral and antiinflammatory effects |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648311B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266699A (en) * | 2000-01-28 | 2000-09-20 | 张文英 | Anti-infectious antipyretic and antalgic medicine |
| CN1561997A (en) * | 2004-04-20 | 2005-01-12 | 成都厚发科技开发有限公司 | Medicinal composition having anti-inflammation and anti-infection function |
| CN1989953A (en) * | 2005-12-26 | 2007-07-04 | 黄振华 | Composition of ambroxol, salt thereof and anti-infective drug |
| CN101073625A (en) * | 2006-05-15 | 2007-11-21 | 广东奇方药业有限公司 | Medicinal composition with anti-infective and anti-inflammatory functions |
| CN101185707A (en) * | 2006-11-23 | 2008-05-28 | 河北智同医药控股集团有限公司 | Antiphlogistic antiviral medicinal composition, and its preparation method and application |
| CN104606288A (en) * | 2015-01-06 | 2015-05-13 | 四川省中医药科学院 | Novel method for preparing total flavonoid aglycone extract of scutellaria baicalensis georgi |
| CN104983944A (en) * | 2015-06-15 | 2015-10-21 | 山东大学 | Compound Chinese herbal medicine anti-microbial anti-viral agent and preparing method and application thereof |
-
2017
- 2017-08-30 CN CN201710759720.XA patent/CN107648311B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266699A (en) * | 2000-01-28 | 2000-09-20 | 张文英 | Anti-infectious antipyretic and antalgic medicine |
| CN1561997A (en) * | 2004-04-20 | 2005-01-12 | 成都厚发科技开发有限公司 | Medicinal composition having anti-inflammation and anti-infection function |
| CN1989953A (en) * | 2005-12-26 | 2007-07-04 | 黄振华 | Composition of ambroxol, salt thereof and anti-infective drug |
| CN101073625A (en) * | 2006-05-15 | 2007-11-21 | 广东奇方药业有限公司 | Medicinal composition with anti-infective and anti-inflammatory functions |
| CN101185707A (en) * | 2006-11-23 | 2008-05-28 | 河北智同医药控股集团有限公司 | Antiphlogistic antiviral medicinal composition, and its preparation method and application |
| CN104606288A (en) * | 2015-01-06 | 2015-05-13 | 四川省中医药科学院 | Novel method for preparing total flavonoid aglycone extract of scutellaria baicalensis georgi |
| CN104983944A (en) * | 2015-06-15 | 2015-10-21 | 山东大学 | Compound Chinese herbal medicine anti-microbial anti-viral agent and preparing method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 包旭，等: "黄心分散片抗菌作用的研究", 《四川生理科学杂志》 * |
| 张曦，等: "黄芩及其有效成分的药理学研究进展", 《天津药学》 * |
| 张玲，等: "穿心莲的提取工艺研究", 《时珍国医国药》 * |
| 李志亨，等: "穿心莲总内酯的研究进展", 《时珍国医国药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107648311B (en) | 2020-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102327368B (en) | Chinese lizardtail rhizome or herb rootstock total effective fraction and preparation method and application thereof | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1923241B (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
| CN108126026A (en) | The preparation method of cordyceps sinensis QISHEN CAPSULE | |
| CN108524685A (en) | A kind of composition that treating children's herpangina and its application | |
| CN106492084A (en) | A kind of pure draft traditional Chinese medicine capable of reducing weight product and preparation method thereof | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN107648311A (en) | With antiviral and composition and medicine of antiinflammatory action | |
| CN102579573A (en) | Salvia miltiorrhiza-radix astragali dripping pill and preparation method thereof | |
| CN108403858A (en) | A kind of beautyberry extract composition that treating hand-foot-and-mouth disease and its application | |
| CN1326552C (en) | Medicine for treating viral influenza, and its prepn. method | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN101856357B (en) | Application of rotundic acid in preparing medicines for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN107334813A (en) | A kind of cubic parthenium extract and its preparation method and purposes | |
| CN104490904B (en) | It is a kind of to treat neurasthenic pharmaceutical composition and preparation method thereof | |
| CN101152355A (en) | Application of ampelopsis extract in preparing medicament for treating hypertension | |
| CN100473398C (en) | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof | |
| CN104523740B (en) | A kind of selaginella doederlleini polyoses extract preparation method and applications | |
| CN101108198B (en) | Epimedium erigeron pharmaceutical composition | |
| CN101284052B (en) | Chinese medicinal materials compound prescription for treating the tumor | |
| CN101375951B (en) | Medicine composition for treating hepatitis B | |
| CN105012400A (en) | Soft traditional Chinese medicine composition capsules for treating cold and preparation method thereof | |
| CN100434426C (en) | Chinese sumac lactone A , preparation method and its use in pharmacy | |
| CN101176772B (en) | Pharmaceutical composition made of cattail pollen and safflower |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240123 Address after: 401519 No.168, xier'an Road, Hechuan Industrial Park, Chongqing Patentee after: CHONGQING HILAN PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: 610041 No. four, South Renmin Road, Sichuan, Chengdu province 51 Patentee before: SICHUAN ACADEMY OF CHINESE MEDICINE SCIENCES Country or region before: China |
|
| TR01 | Transfer of patent right |